{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05308784",
            "orgStudyIdInfo": {
                "id": "myCare-101"
            },
            "organization": {
                "fullName": "Avera McKennan Hospital & University Health Center",
                "class": "OTHER"
            },
            "briefTitle": "A Survey of Physician and Molecular Tumor Board Perspectives on the Clinical Utility and Usability of Cellworks Singula\u2122 and Ventura\u2122 Reports in Facilitating Patient Treatment Decisions for Pan-Cancer Patients",
            "officialTitle": "A Survey of Physician and Molecular Tumor Board Perspectives on the Clinical Utility and Usability of Cellworks Singula\u2122 and Ventura\u2122 Reports in Facilitating Patient Treatment Decisions for Pan-Cancer Patients",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-survey-of-physician-and-molecular-tumor-board-perspectives-on-the-clinical-utility-and-usability-of-cellworks-singula-and-ventura-reports-in-facilitating-patient-treatment-decisions-for-pan-cancer-patients"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-01-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-03-21",
            "studyFirstSubmitQcDate": "2022-04-01",
            "studyFirstPostDateStruct": {
                "date": "2022-04-04",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-07-18",
            "lastUpdatePostDateStruct": {
                "date": "2023-07-19",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Tobias Meissner",
                "investigatorTitle": "Manager -- Cancer Genomics",
                "investigatorAffiliation": "Avera McKennan Hospital & University Health Center"
            },
            "leadSponsor": {
                "name": "Avera McKennan Hospital & University Health Center",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Cellworks Group Inc.",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to determine the benefit of Cellworks Singula\u2122 and Ventura\u2122 reports on physician and molecular tumor board treatment recommendations across a large set of pan-cancer indications. Cellworks reports aim to provide NGS-based therapy recommendations to aid the decision-making of patients, physicians, and molecular tumor boards."
        },
        "conditionsModule": {
            "conditions": [
                "Pan-cancer"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "OTHER",
                "timePerspective": "OTHER"
            },
            "enrollmentInfo": {
                "count": 730,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "interventions": [
                {
                    "type": "OTHER",
                    "name": "Cellworks Singula and Ventura reports",
                    "description": "Personalized drug match reports based on patients' genomic aberration."
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Physician satisfaction on Cellworks reports",
                    "description": "A questionnaire will be administered following receipt of the Cellworks report. Survey questions will be performed using a 6-point forced response Likert scale. Simple descriptive statistics, including medians, mode and range of the resulting Likert scores, will be reported but can lead to incorrect effect size estimates, inflated error rates, and other issues (B\u00fcrkner \\& Vuorre, 2019).\n\nFor hypothesis testing purposes, the proportion of physicians and MTB's with a favorable response (i.e., Likert score of 4 or above) will be estimated along with exact (Clopper-Pearson) 95% two-sided confidence intervals.",
                    "timeFrame": "2022.1 - 2023.1"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "1. Have any stage of cancer for the indications listed at: https://cellworks.life/mycare101 Patients are eligible at any stage of disease.\n2. Expected to be alive 6 months or more\n3. Requirements for NGS testing (e.g., panel or whole-exome sequencing): NGS testing has been ordered from or performed by one or more vendors specified at: https://cellworks.life/mycare101 . NGS reports must be ordered or performed within the last 90 days. Cellworks will accept all NGS input formats available, including PDF, VCF, BAM, and FastQ.\n4. Requirements for additional laboratory testing If Hematological Indication, Cytogenetics in the form of FISH, Karyotyping, IHC, and/or aCGH has been ordered If Acute Myeloid Leukemia (AML), FLT3-itd testing has been ordered If Indication is a form of Brain Cancer (e.g., glioblastoma), Cytogenetics in the form of FISH, Karyotyping, IHC, and/or aCGH has been ordered and MGMT Methylation test has been ordered",
            "healthyVolunteers": false,
            "sex": "ALL",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Patients with a diagnosis of cancer at any stage",
            "samplingMethod": "PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Tobias Meissner, PhD",
                    "role": "CONTACT",
                    "phone": "605-322-3894",
                    "email": "tobias.meissner@avera.org"
                }
            ],
            "locations": [
                {
                    "facility": "Avera McKennan",
                    "status": "RECRUITING",
                    "city": "Sioux Falls",
                    "state": "South Dakota",
                    "zip": "57105",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Tobias Meissner, PhD",
                            "role": "CONTACT",
                            "phone": "605-322-3894",
                            "email": "tobias.meissner@avera.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.54997,
                        "lon": -96.70033
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        }
    },
    "hasResults": false
}